957 related articles for article (PubMed ID: 19173577)
1. Theoretical analysis on the transition state of the anticancer drug trans-[PtCl2(isopropylamine)2] and its cis isomer binding to DNA purine bases.
Zhou L
J Phys Chem B; 2009 Feb; 113(7):2110-27. PubMed ID: 19173577
[TBL] [Abstract][Full Text] [Related]
2. How strong can the bend be on a DNA helix from cisplatin? DFT and MP2 quantum chemical calculations of cisplatin-bridged DNA purine bases.
Burda JV; Leszczynski J
Inorg Chem; 2003 Nov; 42(22):7162-72. PubMed ID: 14577785
[TBL] [Abstract][Full Text] [Related]
3. Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine?
Baik MH; Friesner RA; Lippard SJ
J Am Chem Soc; 2003 Nov; 125(46):14082-92. PubMed ID: 14611245
[TBL] [Abstract][Full Text] [Related]
4. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
5. Trans-diammineplatinum(II): what makes it different from cis-DDP? Coordination chemistry of a neglected relative of cisplatin and its interaction with nucleic acids.
Lippert B
Met Ions Biol Syst; 1996; 33():105-41. PubMed ID: 8742842
[TBL] [Abstract][Full Text] [Related]
6. G-G base-pairing in nucleobase adducts of the anticancer drug cis-[PtCl2(NH3)(2-picoline)] and its trans isomer.
McGowan G; Parsons S; Sadler PJ
Chemistry; 2005 Jul; 11(15):4396-404. PubMed ID: 15880542
[TBL] [Abstract][Full Text] [Related]
7. Theoretical study of cisplatin binding to DNA: the importance of initial complex stabilization.
Raber J; Zhu C; Eriksson LA
J Phys Chem B; 2005 Jun; 109(21):11006-15. PubMed ID: 16852341
[TBL] [Abstract][Full Text] [Related]
8. cis-[PtCl2(4,7-H-5-methyl-7-oxo[1,2,4]triazolo[1,5-a]pyrimidine)2]: a sterically restrictive new cisplatin analogue. Reaction kinetics with model nucleobases, DNA interaction studies, antitumor activity, and structure-activity relationships.
Navarro JA; Salas JM; Romero MA; Vilaplana R; Gonzalez-Vílchez F; Faure R
J Med Chem; 1998 Jan; 41(3):332-8. PubMed ID: 9464364
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and X-ray crystal structure of trans,cis-[Pt(OAc)2I2(en)]: a novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro.
Kratochwil NA; Zabel M; Range KJ; Bednarski PJ
J Med Chem; 1996 Jun; 39(13):2499-507. PubMed ID: 8691447
[TBL] [Abstract][Full Text] [Related]
10. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
[TBL] [Abstract][Full Text] [Related]
11. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
[TBL] [Abstract][Full Text] [Related]
12. GA and AG sequences of DNA react with cisplatin at comparable rates.
Monjardet-Bas V; Bombard S; Chottard JC; Kozelka J
Chemistry; 2003 Oct; 9(19):4739-45. PubMed ID: 14566881
[TBL] [Abstract][Full Text] [Related]
13. Novel binding interactions of the DNA fragment d(pGpG) cross-linked by the antitumor active compound tetrakis(mu-carboxylato)dirhodium(II,II).
Chifotides HT; Koshlap KM; Pérez LM; Dunbar KR
J Am Chem Soc; 2003 Sep; 125(35):10714-24. PubMed ID: 12940757
[TBL] [Abstract][Full Text] [Related]
14. Importance of platinum(II)-assisted platinum(IV) substitution for the oxidation of guanosine derivatives by platinum(IV) complexes.
Choi S; Vastag L; Larrabee YC; Personick ML; Schaberg KB; Fowler BJ; Sandwick RK; Rawji G
Inorg Chem; 2008 Feb; 47(4):1352-60. PubMed ID: 18220340
[TBL] [Abstract][Full Text] [Related]
15. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.
Zaludová R; Natile G; Brabec V
Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyl radical reactions with adenine: reactant complexes, transition states, and product complexes.
Cheng Q; Gu J; Compaan KR; Schaefer HF
Chemistry; 2010 Oct; 16(39):11848-58. PubMed ID: 20878802
[TBL] [Abstract][Full Text] [Related]
17. Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent.
Barry CG; Baruah H; Bierbach U
J Am Chem Soc; 2003 Aug; 125(32):9629-37. PubMed ID: 12904029
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents.
Hollis LS; Sundquist WI; Burstyn JN; Heiger-Bernays WJ; Bellon SF; Ahmed KJ; Amundsen AR; Stern EW; Lippard SJ
Cancer Res; 1991 Apr; 51(7):1866-75. PubMed ID: 2004370
[TBL] [Abstract][Full Text] [Related]
19. A QM/MM study of cisplatin-DNA oligonucleotides: from simple models to realistic systems.
Robertazzi A; Platts JA
Chemistry; 2006 Jul; 12(22):5747-56. PubMed ID: 16710864
[TBL] [Abstract][Full Text] [Related]
20. Electrospray ionization mass spectrometric study of purine base-cisplatin complexes.
Frańska M; Frański R; Schroeder G; Springer A; Beck S; Linscheid M
Rapid Commun Mass Spectrom; 2005; 19(8):970-4. PubMed ID: 15759311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
